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SUMMARY
To know the types of meningococcal strains in Spain, we serotyped and
subtyped 743 Neisseria meningitidis isolates recovered between 1990 and 1992
from patients. A great number of serogroup B, serogroup C and non-groupable
meningoccoci reacted with the serotyping reagents while many serogroup C and
non-groupable isolates did not react with the serosubtyping reagents (78-2% and
54-8 % respectively); only 8-9 % of serogroup B meningococci were non-
subtypeable (NST). Distribution of serotypes was similar in serogroup C and in
non-groupable strains. Isolates showed great variability in antigenic phenotypes
(71 in serogroup B, 20 in serogroup C and 25 in non-groupable meningococci). The
most frequent antigenic combinations were 4 :PI . 15 (39-8%) in serogroup B,
2b: NST (55-8%) in serogroup C and 2b: NST (35-6%) in non-groupable
meningococci.
INTRODUCTION
Meningococci have been classified into 13 serogroups based on their capsular
polysaccharide, further subdivided into serotypes with class 2 or 3 outer membrane
protein (OMP) specific monoclonal antibodies (McAbs) and into subtypes with
class 1 OMP specific McAbs [1].
Serotyping of Neisseria meningitidis is important not only for epidemiological
studies but underpins the development of meningococcal vaccines. Most present or
proposed vaccines to protect against serogroup B disease include class 1 and class
2 or 3 OMP as vaccine components [2, 3].
Serotype and serosubtype reagents have been used in epidemiological studies
and some specific types of strains have been associated with epidemic periods
[4-6].
In Spain, in 1979 there was an epidemic period with an incidence of 17-6 per
100000 inhabitants [7]. This high incidence later declined to 3-5 in 1991. Since
1990 we have included sero/subtyping with specific monoclonal antibodies as
epidemiologic markers for all meningococcal strains studied in our laboratory, in
order to determine if meningococci isolated in Spain are similar to meningococcal
strains from other European countries.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268800051694
Downloaded from https://www.cambridge.org/core. IP address: 83.55.255.202, on 05 Dec 2020 at 00:08:30, subject to the Cambridge Core terms of use, available at
J. A. VAZQUEZ, C. MARCOS AND S. BERRON
MATERIALS AND METHODS
We studied 748 strains of Neisseria meningitidis isolated from patients with
meningococcal disease during 1990-2 from different areas of Spain. These strains
represent about 20 % of the meningococcal disease cases reported in Spain at this
time.
Isolates were confirmed as N. meningitidis in our laboratory as described
previously [7]. Serogroups were determined by slide agglutination. The sera used
were produced in our laboratory by inoculating rabbits using the strains and
inoculation protocol already described [7].
Serotypes and subtypes were determined by a whole cell enzyme-linked
immunoassay (EIA). Antigens were prepared as described by Abdillahi and
Poolman [1]. Monoclonal antibodies with serotype specificities 1, 2a, 2b, 4, 14, 15
and subtype specificities P l . l , P1.2, PI.3, P1.4, PI.6, PI.7, PI.9, PI.10. PI.12,
PI. 14, PI. 15 and PI. 16 were supplied by Dr J. T. Poolman (RIVM, Bilthoven,
The Netherlands).
RESULTS
The distribution of serogroups is shown in Table 1. The majority of isolates were
of serogroup B or C; only a few strains belonged to other serogroups (A, X, Y).
Seventy-three (9-7%) meningococcal strains were non-groupable. A high number
of non-groupable strains were found in 1992 (17-8%).
Serotypes and subtypes of all isolates are shown in Tables 2 and 3. There were
no significant changes in the relative frequency of serotypes amongst serogroup B
strains, serotype 4 being the most prevalent (54-3 %) (Table 2); however, we found
an increase of serotype 14 and a decrease of serotype 2a in serogroup C isolates
from 1-8% and 20% to 8-5% and 10-2% respectively (Table 2). Serotype 2b
characterized 67% of all serogroup C isolates. Serotype 2b was the most frequent
serotype amongst non-groupable isolates (45-2%), followed by serotype 4 (20-5%)
(Table 2). The proportion of non-typable strains was 148%, 41 % and 15-1 % in
serogroup B, C and non-groupable isolates respectively (Table 2).
Serosubtype PI. 15, which was frequently linked to serotype 4 (Table 3),
characterized 47'6% of all serogroup B isolates (Table 2). We did not find any
strain of serosubtype PI.4 during 1990 while this serosubtype represented 4-5%
of all isolates in 1991 and 1992. The proportion of non-subtypable strains was
8-9% amongst serogroup B meningococci.
The majority of serogroup C meningococci were non-subtypable with this
serosubtype reagent panel (78-2%) (Table 2), although the proportion fell from
89-1 % in 1990 to 62-7% in 1992. Serosubtype Pl . l , 2 was most commonly found
amongst serogroup C isolates (10-6%) (Table 2). We did not find this serosubtype
in 1990 but its proportion increased to 8-4% in 1991 and to 237% in 1992.
Serosubtype PI.2 increased from 1-8% to 6-8%.
Forty non-groupable strains (54-8%) were non-subtypable (Table 2).
Serosubtypes P l . l , 2 (10-9%) and PI.15 (9-6%) were the most common amongst
this serogroup.
We found 116 different antigenic phenotypes (71 amongst serogroup B, 20
amongst serogroup C and 25 amongst non-groupable strains) (Table 3). The most
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frequent serotype of serogroup B meningococci was the 4: PI. 15 (39-7%) followed
by the 15:P1.7, 16, the 15:P1.16 and the NT:P1.15 with 5-7%, 5-3% and 4-4%
respectively, while 15 strains (3-2%) were non-typable and non-subtypable in
this serogroup. The most frequent phenotypes amongst serogroup C isolates were
2b:NST (55-8%) and 2a:XST (15-2%), while five isolates (2-5%) did not react
with any of the serotype or serosubtype antibodies. The most common serotype-
serosubtype combinations were 2b:NST (35-6%), 2b:Pl . l , 2 (9-6%) and 4:P1.15
(8-2%) in non-groupable meningococci. Six strains (8'2%) were both non-typable
and non-subtypable in this group.
DISCUSSION
Serogroup B strains predominated in causing meningococcal disease in Spain
during epidemic periods in the 1970s and 1980s [8, 9]; serogroup C strains, about
3% in the 1970s [8] and 12-14% in the 1980s [9], made up about 25% of all
meningococcal strains during the last 3 years. The great number of non-groupable
isolates (17-8%) found in 1992 was surprising (Table 1); the majority of these
strains were non-groupable because they showed autoagglutination in saline.
When we analysed the serotype distribution (Table 2) within the three serogroups
(B, C and non-groupable), we found that it was similar between serogroup C and
non-groupable strains. Therefore, we think that perhaps most of these non-
groupable meningococci could be serogroup C isolates which have lost totally or
partially their capsular polysaccharide. Serogroup A strains which made up about
15% of the total in the 1970s [8], were identified only sporadically in the early
1990s.
It is very interesting to note that in this study the great majority of
meningococcal isolates reacted with serotype antibodies regardless of whether
they were serogroup B, C or non-groupable isolates (85-2%, 95-9% and 84-9%
respectively). Only 89 strains (12%) were non-serotypable, this proportion being
lower than that found by other authors in different European countries [5, 6, 10].
However, the number of non-subtypable strains was very different in the three
meningococcal serogroups: 42 (8-9%) in serogroup B, 154 (78-2%) in serogroup C
and 40 (54-8%) in non-groupable strains. We think that the serotype reagents
used in this study provide useful data in epidemiological studies in Spain.
Although most serogroup B meningococcal strains were subtyped, this was not the
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Table 2. Relative distribution of serotypes and subtypes expressed as percentage among
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case for serogroup C isolates, so new subtype reagents are required for this group
of meningococci.
More than 50 % of serogroup B meningococci were serotype 4 and almost 50 %
of these serotype 4 strains reacted with the PI. 15 monoclonal subtype reagent. In
fact, the most common combination of serotype and serosubtype in serogroup B
strains was 4:PI. 15; however, the phenotype 15:PI. 16 which has been associated
with outbreaks in northern Europe [11, 12] only represented 5-3% of all serogroup
B meningococci in this study; Saez-Nieto and colleagues [13] found that serotype
2 was the most common amongst serogroup B meningococci during 1978—80 (years
of higher incidence of meningococcal disease in Spain) followed by serotype 15
strains; they did not find any serotype 4 isolates. These proportions did not change
until 1987, when serotype 15 became the most common amongst serogroup B
meningococci in Spain [14], the proportion of serotype 4 strains diminishing.
These studies were performed using double immunodiffusion in gel [13]. Roman
and colleagues [14] studied the serosubtype of 215 serogroup B serotype 15
meningococcal strains isolated in Spain from 1978-87, and found about 50% were
PI.16 and 50% were PI.15 (linked frequently to serotype 4). We found the
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Table 3. Major antigenic phenotypes of Neisseria meningitidis isolated from
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phenotype B:4:P1.15 the most common in a previous study [9] with a selection
of strains from the 1986-90 period. It would be interesting to know if some
serotype 15 meningoeocci as classified by Roman and colleagues [14] are in fact
serotype 4 meningococcal strains or alternatively whether there has been an
important epidemiological shift in the frequency of serotypes amongst Spanish
serogroup B isolates. We think that many meningoeocci classified as serotype 15
by immunodiffusion may be serotype 4 strains with non-specific reactivity with
serotype 15; further studies with these strains should be performed. The
phenotype B : 2, very frequent during the previous epidemic period [13], was found
very rarely (l-9%) in this study.
The most common serotype amongst serogroup C meningoeocci was 2b. A
previous Spanish study showed a similar proportion of 2a and 2b serotype strains
amongst serogroup C meningoeocci from 1978-87 [14]. However, serotype 2a has
been isolated less frequently in the 1990s.
Some experimental vaccines against serogroup B meningococcal disease have
been tested in Norway. Cuba and Chile [2, 3, 15]. The Cuban vaccine was prepared
using the B: 4: PI. 15 epidemic strain, which is the most frequent phenotype found
in this study amongst serogroup B meningoeocci (39-7%). It would be interesting
to carry out an evaluation of the efficacy of this vaccine in our country. Also, a
polyvalent serogroup B class 1 OMP vaccine, active against all detectable
serosubtypes, is under investigation; as we found that only 8-9% of the serogroup
B strains in Spain were non-subtypeable, such a polyvalent vaccine could in
theory give protection against more than 90% of meningococcal disease in Spain.
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